# Enliven Therapeutics, Inc. (ELVN) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Enliven Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ELVN/mda/fy2025/): filed 2026-03-03; accession 0001193125-26-088232 (https://www.sec.gov/Archives/edgar/data/1672619/000119312526088232/elvn-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/ELVN/mda/fy2024/): filed 2025-03-13; accession 0000950170-25-038758 (https://www.sec.gov/Archives/edgar/data/1672619/000095017025038758/elvn-20241231.htm)
- [FY 2023 MD&A](/company/ELVN/mda/fy2023/): filed 2024-03-14; accession 0000950170-24-031495 (https://www.sec.gov/Archives/edgar/data/1672619/000095017024031495/elvn-20231231.htm)
- [FY 2022 MD&A](/company/ELVN/mda/fy2022/): filed 2023-02-10; accession 0001564590-23-001729 (https://www.sec.gov/Archives/edgar/data/1672619/000156459023001729/imra-10k_20221231.htm)
- [FY 2021 MD&A](/company/ELVN/mda/fy2021/): filed 2022-03-15; accession 0001564590-22-010216 (https://www.sec.gov/Archives/edgar/data/1672619/000156459022010216/imra-10k_20211231.htm)

Back to /company/ELVN/